| 1 |
34655821 | Supraprophylactic Anti-Factor Xa Levels Are Associated with Major Bleeding in Neurosurgery Patients Receiving Prophylactic Enoxaparin. | 2022 Jan |
1 |
| 2 |
35100448 | Evaluation of anti-factor Xa concentrations using a body mass index-based enoxaparin dosing protocol for venous thromboembolism prophylaxis in trauma patients. | 2022 Mar |
1 |
| 3 |
32888192 | Continuous intravenous infusion of enoxaparin controls thrombin formation more than standard subcutaneous administration in critically ill patients. A sub-study of the ENOKSI thromboprophylaxis RCT. | 2021 Jan |
1 |
| 4 |
33400099 | Comparison of two escalated enoxaparin dosing regimens for venous thromboembolism prophylaxis in obese hospitalized patients. | 2021 Aug |
1 |
| 5 |
33512867 | Enoxaparin Dose Requirements to Achieve Therapeutic Low-molecular-weight Heparin Anti-factor Xa Levels in Infants and Young Children. | 2021 Oct 1 |
5 |
| 6 |
34078133 | Safety and Efficacy of Prophylactic Enoxaparin Adjusted by Anti-Factor Xa Peak Levels in Pancreatic Surgery. | 2021 Jun 2 |
2 |
| 7 |
34402789 | Bioavailability study of Enoxaparin Sodium Chemi (80 mg/0.8 mL) and Clexane (80 mg/0.8 mL) subcutaneous injection in healthy adults. | 2021 Nov |
1 |
| 8 |
34733033 | Factor Xa Levels in Patients Receiving Prophylactic Enoxaparin Sodium in the Intensive Care Unit of an Academic Hospital. | 2021 Aug |
4 |
| 9 |
34781984 | Standard- versus intermediate-dose enoxaparin for anti-factor Xa guided thromboprophylaxis in critically ill patients with COVID-19. | 2021 Nov 15 |
3 |
| 10 |
34884411 | Anti-Xa Activity of Enoxaparin for Prevention of Venous Thromboembolism in Severe Nephrotic Syndrome-A Single Center Prospective Study. | 2021 Dec 6 |
1 |
| 11 |
31463801 | Prophylactic Use of Enoxaparin in Adolescents During Bariatric Surgery-a Prospective Clinical Study. | 2020 Jan |
1 |
| 12 |
31843692 | Prophylactic Enoxaparin Adjusted by Anti-Factor Xa Peak Levels Compared with Recommended Thromboprophylaxis and Rates of Clinically Evident Venous Thromboembolism in Surgical Oncology Patients. | 2020 Mar |
1 |
| 13 |
31986476 | Supplementation with antithrombin III ex vivo optimizes enoxaparin responses in critically injured patients. | 2020 Mar |
1 |
| 14 |
32045583 | Fixed or Weight-Tiered Enoxaparin After Thoracic Surgery for Venous Thromboembolism Prevention. | 2020 Jun |
1 |
| 15 |
32391762 | Early Anti-Xa Assay-Guided Low Molecular Weight Heparin Chemoprophylaxis Is Safe in Adult Patients with Acute Traumatic Brain Injury. | 2020 Apr 1 |
1 |
| 16 |
32559127 | Anti-Factor Xa Levels in Low-weight Surgical Patients Receiving Enoxaparin for Venous Thromboembolism Prophylaxis: A Prospective Cohort Study. | 2020 Jan-Dec |
2 |
| 17 |
32624425 | Rethinking the one-size-fits-most approach to venous thromboembolism prophylaxis after radical cystectomy. | 2020 Oct |
1 |
| 18 |
33086312 | Low anti-Factor Xa level predicts 90-day Symptomatic Venous Thromboembolism in Surgical Patients Receiving Enoxaparin Prophylaxis: A Pooled Analysis of Eight Clinical Trials. | 2020 Oct 19 |
1 |
| 19 |
33155833 | Which Trauma Patients Require Lower Enoxaparin Dosing for Venous Thromboembolism Prophylaxis? | 2020 Oct |
1 |
| 20 |
30698331 | An in vitro study to investigate the interference of enoxaparin on plasma levels of direct oral factor Xa inhibitors measured by chromogenic assays. | 2019 Jun |
2 |
| 21 |
31112313 | Enoxaparin Thromboprophylaxis Dosing and Anti-Factor Xa Levels in Low-Weight Patients. | 2019 Jul |
1 |
| 22 |
31116389 | Assessment of Anti-Factor Xa Levels of Patients Undergoing Colorectal Surgery Given Once-Daily Enoxaparin Prophylaxis: A Clinical Study Examining Enoxaparin Pharmacokinetics. | 2019 Aug 1 |
1 |
| 23 |
28736059 | Anti-Factor Xa measurements in acute care surgery patients to examine enoxaparin dose. | 2018 Aug |
1 |
| 24 |
29367044 | Trauma patients with lower extremity and pelvic fractures: Should anti-factor Xa trough level guide prophylactic enoxaparin dose? | 2018 Mar |
2 |
| 25 |
29490713 | Establishment of prophylactic enoxaparin dosing recommendations to achieve targeted anti-factor Xa concentrations in children with CHD. | 2018 May |
3 |
| 26 |
29626461 | Enoxaparin 40 mg per Day Is Inadequate for Venous Thromboembolism Prophylaxis After Thoracic Surgical Procedure. | 2018 Aug |
1 |
| 27 |
27936527 | Individualized dosing of enoxaparin in a morbidly obese patient by monitoring the anti-factor Xa. | 2017 Feb |
1 |
| 28 |
28467656 | Direct Oral Anticoagulants Vs. Enoxaparin for Prevention of Venous Thromboembolism Following Orthopedic Surgery: A Dose-Response Meta-analysis. | 2017 Jul |
1 |
| 29 |
28808492 | Assessment of anti-factor Xa activity of enoxaparin for venous thromboembolism prophylaxis in morbidly obese surgical patients. | 2017 Jul-Sep |
1 |
| 30 |
28846877 | Plasma anti-FXa concentration after continuous intravenous infusion and subcutaneous dosing of enoxaparin for thromboprophylaxis in critically ill patients. A randomized clinical trial. | 2017 Oct |
2 |
| 31 |
28918992 | Anti-factor Xa levels in patients undergoing laparoscopic sleeve gastrectomy: 2 different dosing regimens of enoxaparin. | 2017 Oct |
2 |
| 32 |
27256341 | The use of anti-factor Xa monitoring in a selection of patients receiving enoxaparin at a large academic medical center. | 2016 Nov |
1 |
| 33 |
27383732 | Association Between Enoxaparin Dosage Adjusted by Anti-Factor Xa Trough Level and Clinically Evident Venous Thromboembolism After Trauma. | 2016 Nov 1 |
2 |
| 34 |
27440463 | Adjusting enoxaparin dosage according to anti-FXa levels and pregnancy outcome in thrombophilic women. A randomised controlled trial. | 2016 Sep 27 |
1 |
| 35 |
27693871 | Supratherapeutic anti-factor Xa levels in patients receiving prophylactic doses of enoxaparin: A case series. | 2016 |
3 |
| 36 |
25325764 | A practical approach to the use of low molecular weight heparins in VTE treatment and prophylaxis in children and newborns. | 2015 Feb |
1 |
| 37 |
25716128 | Use of Enoxaparin in Obese Adolescents During Bariatric Surgery--a Pilot Study. | 2015 Oct |
1 |
| 38 |
24335994 | IV enoxaparin in pediatric and cardiac ICU patients. | 2014 Feb |
1 |
| 39 |
24458050 | Effect of a dalteparin prophylaxis protocol using anti-factor Xa concentrations on venous thromboembolism in high-risk trauma patients. | 2014 Feb |
1 |
| 40 |
24943261 | Lack of anti-factor Xa assay standardization results in significant low molecular weight heparin (enoxaparin) dose variation in neonates and children. | 2014 Sep |
1 |
| 41 |
25526009 | Bullous hemorrhagic dermatosis distant from the site of heparin injection. | 2014 Oct 15 |
1 |
| 42 |
23533746 | The efficacy and safety of rivaroxaban for venous thromboembolism prophylaxis after total hip and total knee arthroplasty. | 2013 |
1 |
| 43 |
23808469 | Direct thrombin inhibitors and factor xa inhibitors can influence the diluted prothrombin time used as the initial screen for lupus anticoagulant. | 2013 Jul |
1 |
| 44 |
27121789 | Investigation of Pharmacodynamic and Pharmacokinetic Interactions Between Rivaroxaban and Enoxaparin in Healthy Male Subjects. | 2013 Jul |
1 |
| 45 |
22565589 | Prospective comparison of three enoxaparin dosing regimens to achieve target anti-factor Xa levels in hospitalized, medically ill patients with extreme obesity. | 2012 Jul |
3 |
| 46 |
22876779 | Prevention of venous thromboembolism with new oral anticoagulants versus standard pharmacological treatment in acute medically ill patients: a systematic review and meta-analysis. | 2012 Sep 10 |
3 |
| 47 |
23227470 | Bioactivity of enoxaparin in critically ill patients with normal renal function. | 2012 Nov |
3 |
| 48 |
20972772 | Comparative study of Factor Xa fluorogenic substrates and their influence on the quantification of LMWHs. | 2011 Jan |
1 |
| 49 |
21083516 | Effects of enoxaparin preparations on thrombin generation and their correlation with their anti-FXa activity. | 2011 Jan |
1 |
| 50 |
21150227 | Effects of nadroparin, enoxaparin, and unfractionated heparin on endogenous formation of factor Xa and IIa and on thrombelastometry profiles in cord versus adult blood. | 2011 |
3 |